Abstract
“Modern medicine is entering the “molecular age” — a statement similar to this is frequently found not only in the writings of physicians and scientists, but also in the mass media. Like many of the paradigm shifts that have characterized technical progress in the medical arena, the characterization of diseases at the level of genes and molecules is only the latest step in the search for the final frontier of medicine. Over the past centuries, medical research has continuously refined its level of organization, as it has focussed on the whole body, then on the levels of the organ, the cell, and now, finally, on molecules and genes. The term “molecular medicine” describes the impact of molecular biology and genetics on medicine and characterizes a new field devoted to the search for molecular aspects in disease etiology, but also to the potential use of the resulting new technology for molecular diagnosis and therapy. The human genome project has now been completed, generating an abundance of new genetic information that can be applied to medicine. New candidate genes for human disease will be defined and will be tested in functional models. This information can be used in many ways: DNA technology has been and will be useful to define genetic risk factors for diseases long before they appear, opening the door for preventive strategies. Furthermore, this genetic information can be used to optimize conventional pharmacological treatment, improving the rate of responders to drug treatment which is currently low in many situations. This means that the individual gene profile can be used to choose the best treatment option for the patient. Lastly, gene therapeutic approaches have been proposed using somatic gene transfer technology. These techniques are targeting the repair of defective genes, altering gene regulation by increasing “good” genes and inhibiting “bad” genes. Alternatively, functional genes can be applied to replace defective genes or genes thought to be protective for defined pathophysiological conditions can be added to the organism. All these approaches offer many new and fascinating ways to allow for tremendous progress in medicine.
“ I was led to remark that, whereas, in the beginning, the difficulty had been to throw off the body of Jekyll, it had of late gradually but decidedly transferred itself to the other side. All things therefore seemed to point to this: that I was slowly losing hold of my original and better self, and becoming slowly incorporated with my second and worse.”
From “The strange case of Dr. Jekyll and Mr. Hyde” by Robert Louis Stevenson. 1886
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997 Oct 15; 278 (15): 1242–50
Paul M, Wagner J, Hoffmann S, Urata H, Ganten D. Transgenic rats: new experimental models for the study of candidate genes in hypertension research. Annu Rev Physiol 1994; 56: 811–29
Paul M, Wagner J. Transgenic animals as models to study the regulation and functional role of the renin-angiotensin system. Exp Nephrol 1994 Mar-Apr; 2(2): 128
Moreadith RW, Radford NB. Gene targeting in embryonic stem cells: the new physiology and metabolism. J Mol Med 1997 Mar; 75 (3): 208–16
Grody WW. Cystic fibrosis. Arch Pathol Lab Med 1999 Nov; 123 (11): 1041–6
Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Ther Drug Monit 1998 Oct; 20 (5): 517–24
Lown, KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage, LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997, 99, 2545–2553
Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, Relling MV, Evans WE. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997 Apr 15; 126 (8): 608–14
Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999 Oct 15; 286 (5439): 487–91
Kurian KM, Watson CJ, Wyllie AH. DNA chip technology. JPathol 1999 Feb; 187 (3): 267–71
Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson, ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patientswith cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999 Mar 20; 353 (9157): 947–54
CNN.com. FDA suspends gene therapy studies after PENN death. October 11, 1999
Kielian T, Hickey WF. Inflammatory thoughts about glioma gene therapy. Nature Med 1999, 5: 1237–1238
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Paul, M. (2001). The Strange Case of Molecular Medicine. In: Willich, S.N., Elm, S. (eds) Medical Challenges for the New Millennium. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9708-1_8
Download citation
DOI: https://doi.org/10.1007/978-94-015-9708-1_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-5685-6
Online ISBN: 978-94-015-9708-1
eBook Packages: Springer Book Archive